234 related articles for article (PubMed ID: 28267112)
1. PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY.
Garcia Gonzalez JM; Snyder L; Blair M; Rohr A; Shapiro M; Greenwald M
Retina; 2018 Apr; 38(4):764-772. PubMed ID: 28267112
[TBL] [Abstract][Full Text] [Related]
2. The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.
Çömez A; Karaküçük Y; Özmen MC; Çelemler P; Saygılı O
Eye (Lond); 2021 Dec; 35(12):3302-3310. PubMed ID: 33514904
[TBL] [Abstract][Full Text] [Related]
3. [Fluorescence Angiography-assisted Management of Recurrences in Aggressive Posterior Retinopathy of Prematurity (APROP) after Intravitreal Monotherapy with 0.312 mg Bevacizumab].
Andrassi-Darida M; Mais C; Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2020 Dec; 237(12):1468-1476. PubMed ID: 31770787
[TBL] [Abstract][Full Text] [Related]
4. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
[TBL] [Abstract][Full Text] [Related]
5. Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.
Lepore D; Quinn GE; Molle F; Orazi L; Baldascino A; Ji MH; Sammartino M; Sbaraglia F; Ricci D; Mercuri E
Ophthalmology; 2018 Feb; 125(2):218-226. PubMed ID: 28867130
[TBL] [Abstract][Full Text] [Related]
6. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab or laser for aggressive posterior retinopathy of prematurity.
Blair M; Gonzalez JMG; Snyder L; Schechet S; Greenwald M; Shapiro M; Rodriguez SH
Taiwan J Ophthalmol; 2018; 8(4):243-248. PubMed ID: 30637196
[TBL] [Abstract][Full Text] [Related]
8. Fluorescein angiographic features post-intravitreal bevacizumab for retinopathy of prematurity: can they support rescue laser photocoagulation to the avascular retina.
Gonzalez A; Agarwal-Sinha S
Can J Ophthalmol; 2020 Oct; 55(5):373-381. PubMed ID: 32835673
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
10. Aggressive Posterior Retinopathy of Prematurity Treated with Intravitreal Bevacizumab: Late Period Fluorescein Angiographic Findings.
Perente I; Eris E; Seymen Z; Cevik SG; Bekmez S
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1141-1146. PubMed ID: 30895452
[TBL] [Abstract][Full Text] [Related]
11. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA; Geloneck MM; Chuang AZ
Ophthalmology; 2016 Sep; 123(9):1845-55. PubMed ID: 27241619
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Outcomes Between Combined Sparing Laser Photocoagulation and Intravitreal Bevacizumab Treatment Versus Conventional Laser Photocoagulation in Aggressive Posterior Retinopathy of Prematurity.
Ittarat M
J Pediatr Ophthalmol Strabismus; 2021; 58(5):292-297. PubMed ID: 34180288
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
14. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab.
Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G
J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
16. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Severe Retinopathy of Prematurity in Infants with Birth Weight above 1500 Grams at a Referral Center in Turkey.
Gunay M; Celik G; Tuten A; Karatekin G; Bardak H; Ovali F
PLoS One; 2016; 11(8):e0161692. PubMed ID: 27548628
[TBL] [Abstract][Full Text] [Related]
18. Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity.
Toy BC; Schachar IH; Tan GS; Moshfeghi DM
Ophthalmology; 2016 Oct; 123(10):2166-75. PubMed ID: 27506484
[TBL] [Abstract][Full Text] [Related]
19. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression.
Vural A; Ekinci DY; Onur IU; Hergünsel GO; Yiğit FU
Int Ophthalmol; 2019 Oct; 39(10):2267-2274. PubMed ID: 30604251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
